Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Eton Pharmaceuticals (ETON) Gross Margin: 2019-2025

Historic Gross Margin for Eton Pharmaceuticals (ETON) over the last 6 years, with Sep 2025 value amounting to 34.97%.

  • Eton Pharmaceuticals' Gross Margin fell 2607.00% to 34.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 65.88%, marking a year-over-year increase of 2991.00%. This contributed to the annual value of 60.01% for FY2024, which is 655.00% down from last year.
  • Eton Pharmaceuticals' Gross Margin amounted to 34.97% in Q3 2025, which was down 44.48% from 63.00% recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year Gross Margin high stood at 552.13% for Q1 2025, and its period low was 12.18% during Q4 2023.
  • For the 3-year period, Eton Pharmaceuticals' Gross Margin averaged around 100.93%, with its median value being 62.65% (2023).
  • Its Gross Margin has fluctuated over the past 5 years, first plummeted by 720,611bps in 2021, then soared by 48,927bps in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Gross Margin (Quarterly) stood at 93.89% in 2021, then tumbled by 1,905bps to 74.84% in 2022, then plummeted by 6,266bps to 12.18% in 2023, then skyrocketed by 4,342bps to 55.60% in 2024, then slumped by 2,607bps to 34.97% in 2025.
  • Its Gross Margin was 34.97% in Q3 2025, compared to 63.00% in Q2 2025 and 552.13% in Q1 2025.